Canada - français - Health Canada

johnson & johnson inc - benzocaïne - crème - 5% - benzocaïne 5% - antipruritics and local anesthetics

Canada - français - Health Canada

s.c. johnson and son, ltd. - huile minérale; avoine - suspension - 83.85%; 5% - huile minérale 83.85%; avoine 5% - basic ointments and protectants

Canada - français - Health Canada

s.c. johnson and son, ltd. - huile minérale; avoine - liquide - 83.85%; 5% - huile minérale 83.85%; avoine 5% - basic ointments and protectants

Canada - français - Health Canada

johnson & johnson inc - fluorure de sodium - soie dentaire - .15mg - fluorure de sodium .15mg - dental agents

Canada - français - Health Canada

s.c. johnson and son, ltd. - hypochlorite de sodium - solution - 1% - hypochlorite de sodium 1% - disinfectants (for agents used on object)

Canada - français - Health Canada

s.c. johnson and son, ltd. - chlorure de benzalkonium; chlorure d'alkyl diméthyl éthylbenzyl ammonium - solution - 0.11%; 0.11% - chlorure de benzalkonium 0.11%; chlorure d'alkyl diméthyl éthylbenzyl ammonium 0.11% - disinfectants (for agents used on object)

Union européenne - français - EMA (European Medicines Agency)

smithkline beecham plc - la rosiglitazone, la metformine chlorhydrate de - diabète sucré, type 2 - les médicaments utilisés dans le diabète - avandamet est indiqué dans le traitement du diabète de type 2, les patients, particulièrement les patients en surpoids:qui sont incapables de produire suffisamment de contrôle glycémique à leur dose maximale tolérée de l'oral metformine seule. dans la triple thérapie orale avec sulphonylurea chez les patients avec une insuffisance de contrôle glycémique malgré la double traitement par voie orale avec leur dose maximale tolérée de metformine et une sulphonylurea (voir la section 4.

Union européenne - français - EMA (European Medicines Agency)

astellas pharma europe b.v. - enzalutamide - néoplasmes prostatiques - la thérapie endocrinienne - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.

Union européenne - français - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rfp-lt) and avian encephalomyelitis virus, strain calnek 1143 (ae) - immunologicals for aves, live viral vaccines, domestic fowl - poulet - for active immunisation of chickens of 8 to 13 weeks of age in order to reduce the skin lesions due to fowlpox, to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis and to prevent egg production losses due to avian encephalomyelitis.

Union européenne - français - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunologiques pour aves - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).